David Ribeiro, chief executive of ProAxsis , a portfolio company of Netscientific PLC (LON:NSCI) has high hopes for its protease detection, which measures levels of neutrophil elastase, released in sufferers of chronic respiratory disease.
He hopes to develop a monitoring system to track the levels of neutrophil elastase to long term chronic decline in lung function in those afflicted with cystic fibrosis and COPD (chronic obstructive pulmonary disease).
“We’re trying to monitor the disease and get an early warning of when the person is going to get worse by measuring their elastase,” he explains.
“What we’d really like to do is create a simple point of care test the patient can use at a clinic or at home to track elastase levels long term.”
The group is hoping to have the test available early as 2017.
“I am genuinely excited by the challenges I’ve had in the last six months and I’m very excited by the potential for the work that we’re doing,” says Ribeiro.